CANbridge Pharmaceuticals Appoints General Manager of China

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases

CANbridge Pharmaceuticals Completes $43 Million Series E Financing

CANbridge Pharmaceuticals Appoints Head of Global Research

CANbridge Pharmaceuticals Receives Chinese Marketing Approval for Hunterase® First Enzyme Replacement Therapy for Hunter Syndrome in China

CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in Taiwan

CANbridge Pharmaceuticals Appoints Senior Vice President/Global Head of Business Development

CANbridge Pharmaceuticals Enters into Rare Disease Gene Therapy Research Agreement with UMass Medical School